MoonLake Immunotherapeutics

NasdaqCM:MLTX Stock Report

Market Cap: US$3.4b

MoonLake Immunotherapeutics Management

Management criteria checks 2/4

MoonLake Immunotherapeutics' CEO is Jorge da Silva, appointed in Apr 2022, has a tenure of 2.75 years. total yearly compensation is $1.20M, comprised of 48.9% salary and 51.1% bonuses, including company stock and options. directly owns 4.74% of the company’s shares, worth $161.84M. The average tenure of the management team and the board of directors is 1 years and 2.8 years respectively.

Key information

Jorge da Silva

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage48.9%
CEO tenure2.8yrs
CEO ownership4.7%
Management average tenureless than a year
Board average tenure2.8yrs

Recent management updates

Recent updates

We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate

Dec 16
We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold

Oct 13

MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

Aug 27
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

Jul 18

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

May 14
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Feb 26

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Jan 29
We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Oct 16
Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

Jul 26

CEO Compensation Analysis

How has Jorge da Silva's remuneration changed compared to MoonLake Immunotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$81m

Jun 30 2024n/an/a

-US$55m

Mar 31 2024n/an/a

-US$41m

Dec 31 2023US$1mUS$586k

-US$36m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$46m

Mar 31 2023n/an/a

-US$48m

Dec 31 2022US$5mUS$460k

-US$50m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$54m

Dec 31 2021US$5mUS$230k

-US$64m

Compensation vs Market: Jorge's total compensation ($USD1.20M) is below average for companies of similar size in the US market ($USD6.66M).

Compensation vs Earnings: Jorge's compensation has been consistent with company performance over the past year.

CEO

Jorge da Silva (46 yo)

2.8yrs

Tenure

US$1,198,215

Compensation

Dr. Jorge Santos da Silva is a Co-Founder of MoonLake Immunotherapeutics (Alternate name MoonLake Immunotherapeutics AG) and has served as the Chief Executive Officer since April 2022. Dr. da Silva is a Di...

Leadership Team

NamePositionTenureCompensationOwnership
Jorge da Silva
Co-Founder2.8yrsUS$1.20m4.74%
$ 161.8m
Kristian Reich
Co-Founder & Chief Scientific Officer2.8yrsUS$1.23m4.71%
$ 161.0m
Matthias Bodenstedt
Chief Financial Officer2.8yrsUS$891.60k0.84%
$ 28.7m
Oliver Daltrop
Chief Operations Officerless than a yearno datano data
Carla Bretes
Director Investor Relations & Business Developmentless than a yearno datano data
Nicolas Mosimann
General Counsel2.1yrsno datano data
Joana Cortez
Sr. Director Legal & Complianceless than a yearno datano data
Tino Anthamatten
Vice President of Marketingless than a yearno datano data
Luciana Marques
Director of HRless than a yearno datano data
Nuala Brennan
Chief Clinical Development Officer3.3yrsno datano data
Roman Akbar-Haase
Chief of Staff R&Dless than a yearno datano data
Benjamin Porter-Brown
Chief Medical Officerless than a yearno datano data

1.0yrs

Average Tenure

46yo

Average Age

Experienced Management: MLTX's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jorge da Silva
Co-Founder2.8yrsUS$1.20m4.74%
$ 161.8m
Simon Sturge
Independent Chairman of the Board2.8yrsUS$315.49k0.27%
$ 9.3m
Catherine Moukheibir
Independent Director2.8yrsUS$287.49k0%
$ 0
Andrew Phillips
Independent Director2.8yrsUS$280.99k0%
$ 0
Ramnik Xavier
Independent Director2.8yrsUS$299.99k0%
$ 0
Spike Loy
Independent Director2.8yrsUS$277.49k0%
$ 0
Kara Lassen
Independent Director2.8yrsUS$44.00kno data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Board: MLTX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 22:43
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MoonLake Immunotherapeutics is covered by 16 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leon WangBarclays
Alexandru CogutBryan Garnier & Co
Julian HarrisonBTIG